sCD126 as a Prognostic Biomarker in Critical COVID-19: 127 Patient Cohort

127 patients with critical COVID-19 had serum levels of IL-6, soluble CD126, and sgp130 measured within 24 hours of mechanical ventilation and before tocilizumab treatment. The data, published by figshare admin karger, was used to identify a biomarker cut-off predicting clinical outcome on the WHO Clinical Progression Scale by day 28. The primary finding was that sCD126 ≥100ng/ml was independently associated with worse outcome.

Use Cases

• Validate the prognostic cut-off of sCD126 ≥100ng/ml based on the study's regression analysis.
• Model 28-day clinical outcomes based on baseline biomarker levels and patient comorbidities.
• Compare the predictive power of sCD126 against other biomarkers like IL-6 and sgp130 mentioned in the description.
• Investigate biomarker dynamics in critical COVID-19 patients receiving tocilizumab treatment.

Strengths

• Data is from a prospective clinical study of 127 patients, providing a defined cohort.
• Biomarker measurements were taken at a standardized time point (within 24 hours of ventilation and before treatment).
• Outcome is measured against a standardized scale (WHO Clinical Progression Scale).

Limitations

• The dataset is very small (217.5 KB), indicating limited scope and sample size.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect temporal and treatment bias inherent to the specific clinical cohort studied.

Provenance

Source

figshare

Collection Method

Prospective clinical study; serum biomarker measurements.

Freshness

Last updated 2026-04-27 05:55:17; freshness should be verified.